首页|Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
Relapse remains the worst life-threatening complications after allogeneic hematopoietic stem cell transplantation(allo-HSCT)in patients with acute myeloid leukemia(AML),whose prognosis has been historically dismal.Given the rapid development of genomics and immunotherapies,the interfer-ence strategies for AML recurrence have been changing these years.More and more novel targeting agents that have received the U.S.Food and Drug Administration(FDA)approval for de novo AML treat-ment have been administrated in the salvage or maintenance therapy of post-HSCT relapse.Targeted stra-tegies that regulate the immune microenvironment of and optimize the graft versus leukemia(GVL)effect of immune cells are gradually improved.Such agents not only have been proven to achieve clinical benefits from a single drug,but if combined with classic therapies,can significantly improve the poor prognosis of AML patients who relapse after allo-HSCT.This review will focus on currently available and promising upcoming agents and also discuss the challenges and limitations of targeted therapies in the allogeneic hematopoietic stem cell transplantation community.

AMLTargeted therapyRelapseImmune microenvironmentAllogeneic hematopoietic stem cell transplantationOncogenic effectorsMetabolismSurface markers

Wei Shi、Weiwei Jin、Linghui Xia、Yu Hu

展开 >

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430022, China

Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA

Department of Cardiovascular,Optical Valley School District,Hubei Provincial Hospital of Traditional Chinese Medicine,Wuhan 430061,China

Hubei Province Academy of Traditional Chinese Medicine,Wuhan 430074,China

展开 >

This work was supported by the National Natural Science Foun-dation of ChinaCollaborative Innovation Center of Hematology,China.We thank Dr.Stephanie J.Lee of Fred Hutchinson Cancer Research Center fo

81302043

2020

药学学报(英文版)

药学学报(英文版)

CSTPCDCSCDSCI
ISSN：
年,卷(期)：2020.10(11)
  • 1
  • 1